Classifying tumors by organ, such as breast or brain, ignores the genetic, biologic, and patient-related factors that make cancer cases unique. Cancer therapy is therefore moving from a one-size-fits-all paradigm to one of greater personalization. Using an in-house established platform, based on an assembly of benchtop instruments, researchers in the Remke Lab at the University of Dusseldorf Medical School have developed a system that will help guiding oncologists toward the right treatments, at the right time, for the right patients.
Based on quantitative, high-throughput screening, this approach will contribute to uncover optimal treatment choices from libraries of approved and late development-stage anticancer drugs. This highly sensitive, cell-based screening platform allows low-volume, multiple-concentration assays to support informed decision-making. The ultimate goal of this research is to enable truly personalized treatment regimens for life-threatening cancers.
Dependable, creative, and capable scientists, Nan Qin and her colleagues, have developed a semi-automated high-throughput drug screening platform in the Department for Pediatric Oncology, Hematology and Clinical Immunology at the Children’s Clinic of the University Hospital in Düsseldorf.
In the past 5 years, they have successfully screened more than 100 primary cultures of patient-derived tumor cells and more than 150 established cell lines from a wide variety of tumor entities using drug libraries comprising about 250-650 compounds. They have extensive experience in sample preparation and processing of in vitro high-throughput drug screening and evaluation and annotation of the corresponding data.